Welcome to our dedicated page for AINOS SEC filings (Ticker: AIMDW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ainos, Inc. (AIMDW) SEC filings page provides access to regulatory documents that describe the company’s capital structure, warrant listing, and material events affecting its AI and SmellTech business. AIMDW represents warrants to purchase Ainos common stock, which are listed on The Nasdaq Stock Market LLC, and the company reports developments related to these securities and its common stock through current reports on Form 8-K and other filings.
In its SEC disclosures, Ainos identifies itself as a Texas corporation with Commission File Number 001-41461. Filings detail actions such as an At The Market Offering Agreement for issuing common stock through a placement agent, including prospectus supplements that adjust the aggregate offering amount. Other documents describe a 1-for-5 reverse stock split of the company’s common stock, effective June 30, 2025, with the stock trading on a split-adjusted basis on Nasdaq from that date and cash in lieu of fractional shares.
Form 8-K reports also cover topics such as changes in the company’s independent registered public accounting firm, strategic orders and partnerships for AI Nose deployment in semiconductor manufacturing, and the furnishing of earnings press releases. These filings help explain how Ainos is financing its operations, managing its audit relationships, and formalizing commercial agreements around its AI Nose and SmellTech-as-a-Service platform.
On Stock Titan, Ainos filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, making it easier to understand the implications of items like capital raises, reverse splits, or partnership announcements. Users can quickly review 8-Ks related to AIMDW and AIMD, and connect those disclosures to the company’s broader strategy in AI-powered scent digitization and its dual-platform AI and biotech model.
Ainos, Inc. director TSAI CHUN-JUNG received equity compensation through restricted stock units that immediately converted into common shares. On the transaction date, 330,000 RSUs were granted and vested under the Ainos, Inc. 2023 Stock Incentive Plan and then converted into 330,000 shares of common stock at a stated price of $1.61 per share. Following these transactions, TSAI directly holds 686,999 shares of Ainos common stock. These are compensation-related awards rather than open-market purchases or sales.
Ainos, Inc. director TSAI CHUN-JUNG received equity compensation through restricted stock units that immediately converted into common shares. On the transaction date, 330,000 RSUs were granted and vested under the Ainos, Inc. 2023 Stock Incentive Plan and then converted into 330,000 shares of common stock at a stated price of $1.61 per share. Following these transactions, TSAI directly holds 686,999 shares of Ainos common stock. These are compensation-related awards rather than open-market purchases or sales.
Ainos, Inc. director and CEO Tsai Chun-hsien reported equity awards and a conversion on April 15, 2026. He received 300,000 RSUs that vested under the Ainos, Inc. 2023 Stock Incentive Plan, which were then converted into 300,000 shares of Common Stock. A related award entry shows these 300,000 Common shares at $1.61 per share, bringing his directly held Common Stock to 710,372 shares after the transactions. No open-market purchases or sales were reported; all activity reflects compensation-related grants and a derivative conversion.
Ainos, Inc. director and CEO Tsai Chun-hsien reported equity awards and a conversion on April 15, 2026. He received 300,000 RSUs that vested under the Ainos, Inc. 2023 Stock Incentive Plan, which were then converted into 300,000 shares of Common Stock. A related award entry shows these 300,000 Common shares at $1.61 per share, bringing his directly held Common Stock to 710,372 shares after the transactions. No open-market purchases or sales were reported; all activity reflects compensation-related grants and a derivative conversion.
Ainos, Inc. director Lee Ting-chuan reported equity compensation activity involving restricted stock units (RSUs) that converted into common shares. On April 15, 2026, he received 570,000 RSUs granted and vested under the Ainos, Inc. 2023 Stock Incentive Plan, which were then converted into 570,000 shares of common stock at a reported value of $1.61 per share. After these award and conversion transactions, Lee directly holds 935,707 shares of Ainos common stock. These are compensation-related acquisitions rather than open-market purchases or sales.
Ainos, Inc. director Lee Ting-chuan reported equity compensation activity involving restricted stock units (RSUs) that converted into common shares. On April 15, 2026, he received 570,000 RSUs granted and vested under the Ainos, Inc. 2023 Stock Incentive Plan, which were then converted into 570,000 shares of common stock at a reported value of $1.61 per share. After these award and conversion transactions, Lee directly holds 935,707 shares of Ainos common stock. These are compensation-related acquisitions rather than open-market purchases or sales.
ASE Test, Inc., a 10% owner of Ainos, Inc., reported an open-market purchase of 6% Convertible Notes due 2027. The transaction covers 5,994 units of the note, each currently convertible into Ainos common stock at a $22.50 per share conversion price. Following this transaction, ASE Test, Inc. holds 105,868 units of the convertible note. The notes bear 6% compounded interest and have a maturity date extended to March 12, 2027 under an amended agreement.
ASE Test, Inc., a 10% owner of Ainos, Inc., reported an open-market purchase of 6% Convertible Notes due 2027. The transaction covers 5,994 units of the note, each currently convertible into Ainos common stock at a $22.50 per share conversion price. Following this transaction, ASE Test, Inc. holds 105,868 units of the convertible note. The notes bear 6% compounded interest and have a maturity date extended to March 12, 2027 under an amended agreement.
ASE Technology Holding and subsidiary ASE Test, Inc. report beneficial ownership of 667,085 shares of Ainos, Inc. common stock, representing 8.4% of the class. This stake combines 11,777 shares held directly with shares issuable from a $2,000,000 2023 convertible note, a $9,000,000 2024 convertible note, and a warrant for 100,000 shares, all reflecting a one-for-five reverse stock split completed in June 2025. The notes bear 6% compound interest and are convertible primarily at $22.50 per share. ASE Test Taiwan has also granted Ainos KY broad voting discretion over its Ainos shares and agreed to annual transfer limits, underscoring a long-term, structured investment relationship.
ASE Technology Holding and subsidiary ASE Test, Inc. report beneficial ownership of 667,085 shares of Ainos, Inc. common stock, representing 8.4% of the class. This stake combines 11,777 shares held directly with shares issuable from a $2,000,000 2023 convertible note, a $9,000,000 2024 convertible note, and a warrant for 100,000 shares, all reflecting a one-for-five reverse stock split completed in June 2025. The notes bear 6% compound interest and are convertible primarily at $22.50 per share. ASE Test Taiwan has also granted Ainos KY broad voting discretion over its Ainos shares and agreed to annual transfer limits, underscoring a long-term, structured investment relationship.
Ainos, Inc. reported full-year 2025 results and highlighted early commercialization of its AI Nose platform. Revenue reached $124,157, up about 499% from 2024, with gross margin turning positive at roughly 82.9% after a prior-year gross loss.
Despite this top-line growth, Ainos posted a net loss of about $14.8 million, similar to 2024, as operating expenses were roughly $14.1 million. Cash and cash equivalents fell to about $417,353 versus $3.9 million a year earlier. After year-end the company raised NTD 90 million (approximately $2.82 million) to support operations and AI Nose deployment.
For 2026, Ainos is rolling out AI Nose in semiconductor environments, including around 200 systems for front-end wafer fabs and about 1,400 systems under a three-year $2.1 million deployment in semiconductor packaging and testing, with a potential roadmap to scale substantially if validations succeed.
Ainos, Inc. reported full-year 2025 results and highlighted early commercialization of its AI Nose platform. Revenue reached $124,157, up about 499% from 2024, with gross margin turning positive at roughly 82.9% after a prior-year gross loss.
Despite this top-line growth, Ainos posted a net loss of about $14.8 million, similar to 2024, as operating expenses were roughly $14.1 million. Cash and cash equivalents fell to about $417,353 versus $3.9 million a year earlier. After year-end the company raised NTD 90 million (approximately $2.82 million) to support operations and AI Nose deployment.
For 2026, Ainos is rolling out AI Nose in semiconductor environments, including around 200 systems for front-end wafer fabs and about 1,400 systems under a three-year $2.1 million deployment in semiconductor packaging and testing, with a potential roadmap to scale substantially if validations succeed.
Ainos, Inc. filed Amendment No. 14 to its Schedule 13D updating its ownership in Ainos, Inc., a Texas corporation. The filing reports beneficial ownership of 491,263 shares of common stock, representing 6.76% of the outstanding class. Ainos Inc. (Cayman Islands) also holds sole voting power over 3,536,073 shares, including shares subject to voting agreements with several shareholders and ASE Test, Inc., though these 3,044,810 voting-agreement shares are excluded from its reported beneficial ownership. The amendment notes that Taiwan Carbon Nano Technology Corporation sold 46,000 shares subject to the 2026 Voting Agreement and reiterates that the position is held for investment purposes, while leaving open the possibility of future discussions about strategic transactions.
Ainos, Inc. filed Amendment No. 14 to its Schedule 13D updating its ownership in Ainos, Inc., a Texas corporation. The filing reports beneficial ownership of 491,263 shares of common stock, representing 6.76% of the outstanding class. Ainos Inc. (Cayman Islands) also holds sole voting power over 3,536,073 shares, including shares subject to voting agreements with several shareholders and ASE Test, Inc., though these 3,044,810 voting-agreement shares are excluded from its reported beneficial ownership. The amendment notes that Taiwan Carbon Nano Technology Corporation sold 46,000 shares subject to the 2026 Voting Agreement and reiterates that the position is held for investment purposes, while leaving open the possibility of future discussions about strategic transactions.
Taiwan Carbon Nano Technology Corporation (TCNT) updated its ownership and voting arrangements in Ainos, Inc. TCNT now beneficially owns 989,925 shares of Ainos common stock, representing 13.62% of the outstanding shares, after recent sales including 46,000 shares sold on January 28, 2026.
The filing explains that TCNT originally received Ainos shares in August 2024 under a license agreement, in exchange for granting an exclusive, irrevocable, and perpetual license to certain gas sensor and medical device patents. Ainos later implemented a one‑for‑five reverse stock split and TCNT has been gradually selling shares.
On January 1, 2026, TCNT entered into a voting agreement with Ainos Inc., a Cayman Islands corporation, covering the Ainos shares held by TCNT. Under this agreement, TCNT agreed to vote all of its Ainos voting stock as determined by Ainos KY in its sole discretion, effectively transferring voting control while retaining economic ownership.
Taiwan Carbon Nano Technology Corporation (TCNT) updated its ownership and voting arrangements in Ainos, Inc. TCNT now beneficially owns 989,925 shares of Ainos common stock, representing 13.62% of the outstanding shares, after recent sales including 46,000 shares sold on January 28, 2026.
The filing explains that TCNT originally received Ainos shares in August 2024 under a license agreement, in exchange for granting an exclusive, irrevocable, and perpetual license to certain gas sensor and medical device patents. Ainos later implemented a one‑for‑five reverse stock split and TCNT has been gradually selling shares.
On January 1, 2026, TCNT entered into a voting agreement with Ainos Inc., a Cayman Islands corporation, covering the Ainos shares held by TCNT. Under this agreement, TCNT agreed to vote all of its Ainos voting stock as determined by Ainos KY in its sole discretion, effectively transferring voting control while retaining economic ownership.
Taiwan Carbon Nano Technology Corp, a more than 10% owner of Ainos, Inc., reported selling 46,000 shares of Ainos common stock on January 28, 2026 at an average price of $2.1697 per share for general operating purposes.
After this transaction, the reporting shareholder directly owned 989,925 Ainos common shares.
Taiwan Carbon Nano Technology Corp, a more than 10% owner of Ainos, Inc., reported selling 46,000 shares of Ainos common stock on January 28, 2026 at an average price of $2.1697 per share for general operating purposes.
After this transaction, the reporting shareholder directly owned 989,925 Ainos common shares.
ScentAI Inc., a wholly owned subsidiary of Ainos, Inc., filed a Schedule 13D reporting beneficial ownership of 1,160,000 shares of Ainos common stock, representing 16.50% of the outstanding class. These shares have no voting power for so long as they are held by the wholly owned subsidiary.
ScentAI acquired the 1,160,000 Ainos shares on December 30, 2025 in exchange for 116,000,000 shares of ScentAI common stock. The filing states the stake was acquired for investment and general corporate purposes and notes that ScentAI currently has no specific plans for corporate actions involving Ainos, though it may review and change its intentions over time.
ScentAI Inc., a wholly owned subsidiary of Ainos, Inc., filed a Schedule 13D reporting beneficial ownership of 1,160,000 shares of Ainos common stock, representing 16.50% of the outstanding class. These shares have no voting power for so long as they are held by the wholly owned subsidiary.
ScentAI acquired the 1,160,000 Ainos shares on December 30, 2025 in exchange for 116,000,000 shares of ScentAI common stock. The filing states the stake was acquired for investment and general corporate purposes and notes that ScentAI currently has no specific plans for corporate actions involving Ainos, though it may review and change its intentions over time.
ScentAI Inc., a wholly owned subsidiary of Ainos, Inc., filed a Schedule 13D reporting beneficial ownership of 1,160,000 shares of Ainos common stock, representing 16.50% of the outstanding class. These shares have no voting power for so long as they are held by the wholly owned subsidiary.
ScentAI acquired the 1,160,000 Ainos shares on December 30, 2025 in exchange for 116,000,000 shares of ScentAI common stock. The filing states the stake was acquired for investment and general corporate purposes and notes that ScentAI currently has no specific plans for corporate actions involving Ainos, though it may review and change its intentions over time.